Risk of abemaciclib
nausea, neutropenia, fatigue, diarrhea, abdominal pain, leukopenia, toxicity, dose-limiting, infections, vomiting, anemia, toxicities, decreased appetite, Toxicity, alopecia
ADVERSE REACTIONS, NEUTROPENIA, LEUKOPENIA, INFECTIONS, ANEMIA, ALOPECIA
The most common adverse reactions to abemaciclib (≥ 20%) in clinical studies were diarrhea, neutropenia, fatigue, infections, nausea, abdominal pain, anemia, vomiting, alopecia, decreased appetite and leukopenia. The protocol provides for detailed and careful monitoring of all participants to assess for toxicity and the dose escalation scheme is very conservative. Toxicity data from the current dose level will be collected and reviewed to ensure that there were no severe (dose-limiting) toxicities. Furthermore, by just entering the study, participants will be followed very carefully, in an organized coherent manner, which may also benefit their overall healthcare.